

- in disease pathogenesis. *ScientificWorld J* 2014; 2014:781857.
4. Thon JN, Italiano JE. Platelets: Production, morphology and ultrastructure. *Handb Exp Pharmacol* 2012; :3-22.
 5. Guyton, Hall. *Textbook of medical physiology* 11th Edn. Philadelphia, PA: Saunders/Elsevier;c2006. Chapter 36, Hemostasis and Blood Coagulation 457.
 6. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. *Int J Clin Pract* 2009; 63:1509-1515.
 7. Machlus KR, Italiano JE. The incredible journey: From megakaryocyte development to platelet formation. *J Cell Biol* 2013; 201:785-96.
 8. DP Lokwani. *The ABC of CBC: Interpretation of complete blood count and histogram*. 1st Edn. New Delhi. Jaypee Brothers Medical Publishers 2013; 59-69.
 9. Wiwanitkit V. Plateletcrit, mean platelet volume, platelet distribution width: Its expected values and correlation with parallel red blood cell parameters. *Clin Appl Thromb Hemost* 2004; 10:175-178.
 10. Yilmaz T, Yilmaz A. Relationship between altered platelet morphological parameters and retinopathy in patients with type 2 diabetes mellitus. *J Ophthalmol* 2016; 2016:1-5.
 11. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. *JAMA* 2002; 287:2570-2581.
 12. IDF. *Diabetes Atlas*. 6th Ed. International Diabetes Federation, Brussels, Belgium; 2013.
 13. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010; 87:4-14.
 14. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. *Diabetes atlas*. International diabetes federation. 3rd ed. Belgium: International Diabetes Federation 2006; 103.
 15. Cola C, Brugaletta S, Yuste VM, et al. Diabetes mellitus: A prothrombotic state Implications for outcomes after coronary revascularization. *Vasc Health Risk Manag* 2009; 5:101-19.
 16. Saboor M, Ilyas MS. Platelets structural, functional and metabolic alterations in diabetes mellitus. *Pak J Physiol* 2012; 8:40-43.
 17. Watala C, Boncler M, Pietrucha T, et al. Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: Does increased platelet activation contribute to platelet size heterogeneity? *Platelets* 1999; 10:52-60.
 18. Tschöep D. The activated megakaryocyte-platelet-system in vascular disease: Focus on diabetes. *Semin Thromb Hemost* 1995; 21:152-160.
 19. Leoncini G, Signorello MG, Piana A, et al. Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. *Thromb Res* 1997; 86:153-160.
 20. Small M, Douglas JT, Lowe GD, et al. Effect of insulin therapy on coagulation and platelet function in type II (non-insulin- dependent) diabetes mellitus. *Haemostasis* 1986; 16:417-23.
 21. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. *Lancet* 2005; 365:217-23.
 22. Mohan V, Seedat Y, Pradeepa RG. The rising burden of diabetes and hypertension in Southeast Asian and African Regions: Need for effective strategies for prevention and control in primary health care settings. *Int J Hypertension* 2013; 2013:409083.
 23. Bloch MJ. Worldwide prevalence of hypertension exceeds 1.3 billion. *J Am Society Hypertension* 2016; 10:753-4.
 24. Alwan A. *Global status report on noncommunicable diseases 2010*. Geneva, Switzerland: World Health Organization 2011.
 25. Abebe SM, Berhane Y, Worku A, et al. Prevalence and associated factors of hypertension: A cross-sectional community based study in Northwest Ethiopia. *PLOS ONE* 2015; 10:e0125210.
 26. Kumar J. Epidemiology of hypertension. *Clinical Queries: Nephrol* 2013; 2:56-61.
 27. Gupta R, Khedar RS, Panwar RB. Strategies for better hypertension control in India and other lower middle income countries. *J Assoc Physicians India* 2016; 64:58-64.
 28. Anchala R, Kannuri NK, Pant H, et al. Hypertension in India: A systematic review and meta-analysis of prevalence, awareness, and control of hypertension. *J Hypertens* 2014; 32:1170-7.
 29. Hareesh C, Jyotsna P, Jivarajani P, et al. Prevalence and correlates of hypertension among adults in the urban area of Jamnagar, Gujarat, India. *Electronic Physician* 2010; 2.
 30. Lip GY. Target organ damage and the prothrombotic state in hypertension. *Hypertension* 2000; 36:975-7.
 31. Gasparyan AY, Ayyavazyan L, Mikhailidis DP, et al. Mean platelet volume: A link between thrombosis and inflammation? *Curr Pharm Des* 2011; 17:47-58.
 32. Jones RL, Paradise C, Peterson CM. Platelet survival in patients with diabetes mellitus. *Diabetes* 1981; 30:486-9.
 33. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. *Diabetes Care* 2009; 32:525-7.
 34. Dalamaga M, Karmaniolas K, Lekka A, et al. Platelet markers correlate with glycemic indices in diabetic, but not diabetic-myelodysplastic patients with normal platelet count. *Dis Markers* 2010; 29:55-61.
 35. Khan SH, Ahmad SA. Platelet indices among subjects with and without diabetes mellitus and hypertension: A cross-sectional analysis at Karachi, Pakistan. *J Postgraduate Med Institute* 2015; 29.
 36. Yarlioglu M, Kaya MG, Ardic I, et al. Relationship between mean platelet volume levels and subclinical

- target organ damage in newly diagnosed hypertensive patients. *Blood Press* 2011; 20:92–97.
37. Tsiara S, Elisaf M, Jagroop IA, et al. Platelets as predictors of vascular risk: Is there a practical index of platelet activity? *Clin Appl Thromb Hemost* 2003; 9:177–190.
38. Enawgaw B, Adane N, Terefe B, et al. A comparative cross-sectional study of some hematological parameters of hypertensive and normotensive individuals at the university of Gondar hospital, Northwest Ethiopia. *BMC Hematol* 2017; 17:21.